This invention is directed to quinoline/quinoxaline compounds which inhibit
platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to
pharmaceutical compositions comprising these compounds, and to the use of
these compounds for treating a patient suffering from or subject to
disorders/conditions involving cellular differentiation, proliferation,
extracellular matrix production or mediator release and/or T cell
activation and proliferation.
